0 months ago
Emkay retains Buy on Park Medi World, sees 32% upside
There is a hospital company called Park Medi World.
A financial expert firm called Emkay studies stocks and tells people which ones are good to buy.
Emkay looked at Park Medi World's latest results, which were for the June quarter.
The company made more money than before, and even more than experts expected.
Its revenue went up 19% compared to the same time last year.
Its profit grew even faster, going up 31%.
Because the company is doing so well, Emkay thinks its share price will rise by about 32%.
So Emkay told investors to keep buying the stock and set a higher target price.
The company also plans to add many more hospital beds over the next two years.
Emkay warned that delays in payments from government schemes and new markets are risks to watch.
Emkay Global Financial Services retained its 'Buy' rating on Park Medi World and raised its target price to ₹375 per share from ₹350.
The revised target implies roughly 32% upside from the stock's latest closing price of ₹285 per share.
Q1FY27 revenue rose 19% year-on-year to ₹4.8 billion, driven by 12% growth in average revenue per occupied bed after CGHS rate revision.
EBITDA climbed 20% YoY to ₹1.2 billion while profit after tax grew 31% YoY to ₹825 million, supported by lower interest costs.
Management targets a 45% increase in bed capacity over the next two years, with FY27 guidance of 24% revenue growth and 19% EBITDA growth.
- Who
- Park Medi World, a healthcare company, and Emkay Global Financial Services, a domestic brokerage firm.
- What
- Emkay retained its 'Buy' rating on Park Medi World and raised its target price after the company's June quarter results beat estimates.
- Where
- India, as indicated by rupee-denominated figures, CGHS rates, and the brokerage being a domestic firm.
- When
- Following the Q1FY27 (June quarter) results, reported in 2026.
- Why
- Strong Q1 performance driven by ARPOB growth, rising revenue, EBITDA and PAT, and a clear capacity expansion roadmap.
Key facts
- Rating
- Buy (retained)
- Target price
- ₹375 per share (raised from ₹350)
- Latest closing price
- ₹285 per share
- Implied upside
- ~32%
- Q1FY27 revenue
- ₹4.8 billion, up 19% YoY
- Q1FY27 EBITDA
- ₹1.2 billion, up 20% YoY
- Q1FY27 PAT
- ₹825 million, up 31% YoY
- FY27 guidance
- 24% revenue growth and 19% EBITDA growth








